Analysts Rate Ultragenyx Pharmaceutical as “Moderate Buy”

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average rating of “Moderate Buy” from a total of eighteen research firms currently monitoring the stock, according to a report by Marketbeat. Among these analysts, one has issued a sell recommendation, one has suggested holding the stock, while the remaining sixteen have recommended buying shares of the biopharmaceutical company.

The average twelve-month price target for Ultragenyx, based on analyst coverage over the past year, stands at approximately $65.76. This figure indicates a potential upside for investors amid various ratings and target adjustments made by financial institutions.

Recent Analyst Ratings and Price Target Adjustments

Several prominent firms have recently analyzed Ultragenyx’s stock, leading to adjustments in their ratings and price targets. On January 21, 2024, Weiss Ratings reaffirmed a “sell (e+)” rating for the shares. On January 2, 2024, Bank of America reduced its target price from $72.00 to $58.00 while maintaining a “buy” rating.

Additionally, Wells Fargo & Company lowered its price target from $65.00 to $45.00, assigning an “overweight” rating on December 30, 2023. In contrast, Wedbush reiterated a “neutral” rating with a revised price target set at $25.00 for February 17, 2024. Furthermore, Robert W. Baird also adjusted its target from $72.00 to $47.00, classifying the stock as “outperform” on December 30, 2023.

Institutional Investment Activity and Company Overview

Institutional investors have shown significant interest in Ultragenyx Pharmaceutical, with hedge funds recently altering their positions in the stock. UBS Asset Management Americas LLC increased its holdings by 14.8%, now owning 232,360 shares valued at approximately $8.41 million. Envestnet Asset Management Inc. also lifted its stake by 6.0%, holding 29,956 shares worth about $1.09 million after purchasing additional shares during the second quarter.

Moreover, Fox Run Management LLC acquired a new position valued at $607,000, while Mitsubishi UFJ Asset Management Co., Ltd. raised its stake by 7.0%, owning 6,783 shares now valued at $247,000. Overall, institutional investors and hedge funds own approximately 97.67% of Ultragenyx’s stock, indicating a strong institutional backing for the company.

Founded in 2010 and headquartered in Novato, California, Ultragenyx Pharmaceutical focuses on developing and commercializing therapies for rare and ultra-rare genetic disorders. The company has established expertise in various therapeutic approaches, including protein replacement therapies and gene therapies, to address significant unmet medical needs.

Recently, the firm reported promising results from its late-stage trial for DTX301, an AAV8 gene therapy aimed at treating OTC deficiency. The therapy demonstrated an 18% reduction in ammonia levels compared to a placebo, maintaining normal levels over a period of 36 weeks. This success could advance the program toward potential regulatory and commercial milestones.

In terms of financial performance, Ultragenyx announced its quarterly earnings results on February 12, 2024, reporting an earnings per share (EPS) of ($1.29), which fell short of the consensus estimate of ($1.20) by $0.09. Despite this, the company generated revenue of $207.28 million for the quarter, surpassing analyst expectations of $199.60 million.

The company experienced a year-over-year revenue increase of 25.5%, compared to the same quarter last year. Analysts predict that Ultragenyx will post an EPS of ($5.18) for the current fiscal year.

As of the latest trading session, Ultragenyx’s stock price opened at $21.34, reflecting a 1.7% decrease. The stock has seen a 52-week low of $18.41 and a high of $42.37. With a market capitalization of $2.06 billion and a price-to-earnings ratio of -3.65, the stock continues to attract attention from investors and analysts alike.